ストックスクリーナーアプリを入手
23.29
1.37%
0.245
前日終値:
$23.04
開ける：
$23.04
24時間の取引高:
555.58K
Relative Volume:
0.28
時価総額：
$4.35B
収益：
$219.12M
当期純損益:
$-453.82M
株価収益率:
-5.9705
EPS:
-3.9
ネットキャッシュフロー:
$-419.68M
1週間 パフォーマンス:
-3.13%
1か月 パフォーマンス:
-7.17%
6か月 パフォーマンス:
-20.24%
1年 パフォーマンス:
-17.50%
1日の値動き範囲:
$22.82
$23.42
1週間の範囲:
$21.72
$24.30
52週間の値動き範囲:
$21.62
$44.32
Bridgebio Pharma Inc Stock (BBIO) Company Profile
BBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| BBIO | 23.27 | 4.35B | 219.12M | -453.82M | -419.68M | -3.90 |
| VRTX | 448.35 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.89 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.60 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.28 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.59 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-03 | 開始されました | Oppenheimer | Perform |
| 2024-09-04 | 開始されました | Piper Sandler | Overweight |
| 2024-03-21 | 再開されました | Raymond James | Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-07 | 開始されました | Citigroup | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-19 | 開始されました | Evercore ISI | Outperform |
| 2023-02-06 | 開始されました | Cowen | Outperform |
| 2021-12-27 | 繰り返されました | Mizuho | Buy |
| 2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
| 2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-03-22 | 繰り返されました | Goldman | Buy |
| 2021-02-22 | 再開されました | JP Morgan | Overweight |
| 2021-02-09 | 再開されました | Goldman | Buy |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Neutral |
| 2020-05-19 | 開始されました | BTIG Research | Buy |
| 2020-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-19 | 開始されました | Mizuho | Buy |
| 2019-07-26 | 開始されました | Raymond James | Outperform |
| 2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
| 2019-07-22 | 開始されました | Goldman | Buy |
| 2019-07-22 | 開始されました | JP Morgan | Overweight |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-07-22 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
BBIO (BridgeBio Pharma) 5-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Insider Sell Alert: Brian Stephenson Sells Shares of BridgeBio P - GuruFocus.com
BridgeBio Pharma CEO Neil Kumar sells $613,825 in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma CEO Neil Kumar sells $613,825 in stock - Investing.com
BridgeBio Pharma CFO Brian Stephenson sells shares worth $93,136 - Investing.com
BridgeBio Pharma CFO Brian Stephenson sells shares worth $93,136 By Investing.com - Investing.com UK
Bridge Bio Study Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes in ATTR-CM - DocWire News
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market - Yahoo Finance
399,781 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by First Turn Management LLC - MarketBeat
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically - Yahoo Finance
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be - Simply Wall St
Royce & Associates LP Invests $3.11 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director - BioSpace
Open-Label Extension Data Confirms Sustained Benefit of - GlobeNewswire
BridgeBio's Acoramidis Shows 36% Mortality Reduction in ATTR-CM Trial Extension | BBIO Stock News - StockTitan
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL - The Bakersfield Californian
BridgeBio Pharma Announces Publication in the New England - GlobeNewswire
BBIO FY2024 EPS Estimate Reduced by Cantor Fitzgerald - MarketBeat
Shareholders in BridgeBio Pharma (NASDAQ:BBIO) have lost 44%, as stock drops 12% this past week - Simply Wall St
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $47.57 Average Price Target from Brokerages - MarketBeat
Scotiabank Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $45.00 - MarketBeat
Leerink Partnrs Expects Weaker Earnings for BridgeBio Pharma - MarketBeat
BridgeBio: 2 Weeks Until Major Drug Approval Catalyst — A Buy, With Caveats (BBIO) - Seeking Alpha
Leerink Partnrs Has Negative Outlook of BBIO FY2028 Earnings - MarketBeat
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
BridgeBio Pharma Reports Quarterly Loss Amid Restructuring - TipRanks
BridgeBio Pharma Inc (BBIO) Quarterly 10-Q Report - Quartzy
No-Moat BridgeBio's Valuation Driven by Pending Approval of Acoramidis; Positive Long-Term Outlook - Morningstar
BridgeBio Pharma Inc Reports Q3 2024 Revenue of $2.7 Million, Mi - GuruFocus.com
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates - MSN
BridgeBio Pharma earnings beat by $0.13, revenue topped estimates - Investing.com UK
BridgeBio Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Achondroplasia Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., BridgeBio, QED Therapeutics , Ribomic - Barchart
Achondroplasia Market to Show Remarkable Growth Trends from - openPR
BridgeBio Pharma: Q3 Earnings Snapshot - San Antonio Express-News
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update - The Manila Times
BridgeBio's Acoramidis Nears FDA Approval; $500M Milestone Payment Awaits | BBIO Stock News - StockTitan
WCM Investment Management LLC Purchases 86,987 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Trend Tracker for (BBIO) - Stock Traders Daily
BridgeBio Announces Publication of Case Study Exploring - GlobeNewswire
BridgeBio Dives on Revealing Case Study - Baystreet.ca
BridgeBio's Portfolio Theory Innovation Reshapes Drug Development Strategy | BBIO Stock News - StockTitan
Achondroplasia Market Forecasted to Surge in Coming Years, - openPR
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Increased by Emerald Advisers LLC - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Shares Up 8.3%Still a Buy? - MarketBeat
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
(BBIO) Proactive Strategies - Stock Traders Daily
Seven PDUFA dates on FDA’s November calendar - BioCentury
BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Yahoo Finance
Biotech Stocks Facing FDA Decision In November 2024 - RTTNews
Citigroup Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
Bridgebio Pharma Inc (BBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | Secretary, Treasurer & CFO |
Nov 19 '24 |
Sale |
22.41 |
4,156 |
93,137 |
93,758 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):